- U.S. social and economic trends on worrisome track, survey finds
- McDonald nomination unanimously referred to full Senate
- Chuck Norris honorary chairman of NRA voter registration campaign
- GOP outraged Obamacare investigators able to get coverage with fake IDs
- Family removed from Southwest flight over tweet about rude agent, dad says
- Michael Bloomberg thumbs FAA ban, plots course to Israel
- California bans full-contact football practices in off-season
- Thune: Downed fighter jets show more evidence of separatist capabilities
- Obama tells DNC fundraising crowd: ‘I’m not overly partisan’
- Chambliss: Downed jet ultimately goes back to Putin
Latest Pfizer Inc. Items
The Food and Drug Administration on Friday approved the first generic versions of Pfizer's anti-inflammatory painkiller Celebrex.
The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.
U.S. drugmaker Pfizer said Sunday that it has raised its offer for British rival AstraZeneca for a third time, hiking its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds.
Pfizer Inc. said Friday that the Food and Drug Administration will let the drugmaker apply for approval of its heavily touted experimental breast cancer medicine based on midstage patient testing results.
The CEO of drugmaker Pfizer Inc. is telling the governors of Delaware and Maryland that it's premature to speculate about the potential jobs impact of a merger with British rival AstraZeneca PLC.
The governors of Maryland and Delaware are voicing concern about Pfizer Inc.'s efforts to acquire AstraZeneca PLC.
Despite sharply lower expenses and taxes, Pfizer Inc.'s first-quarter profit dropped 15 percent, due to cheaper generic competition for multiple medicines and some promotion partnerships with other drugmakers ending.
Pharmaceutical giant Pfizer said Friday that it hasn't given up on a deal after British drugmaker AstraZeneca flatly rejected its latest takeover bid, worth $106 billion.
Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.